Cover Image
市場調查報告書

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49) :開發中產品分析

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 364832
出版日期 內容資訊 英文 112 Pages
訂單完成後即時交付
價格
Back to Top
端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49) :開發中產品分析 Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2017
出版日期: 2017年10月10日 內容資訊: 英文 112 Pages
簡介

本報告提供以端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49) 為標的之治療藥開發相關資訊,提供您開發階段,藥物標的,作用機制,給藥途徑及各分子類型分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49)概要

治療藥的開發

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49):開發中的產品 - 各開發階段

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49):開發中的產品 - 各治療範圍

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49):開發中的產品 - 各適應症

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49):企業開發中的產品

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49):大學/機關開發中的產品

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49):治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49)治療藥的開發企業

  • Adamis Pharmaceuticals Corporation
  • Argos Therapeutics, Inc.
  • Asterias Biotherapeutics, Inc.
  • e-Therapeutics Plc
  • F. Hoffmann-La Roche Ltd.
  • Inovio Pharmaceuticals, Inc.
  • Invectys SA
  • Johnson & Johnson
  • Komipharm International Co., Ltd.
  • Mediolanum farmaceutici S.p.A.
  • Ultimovacs AS
  • Vaxon Biotech

藥物簡介

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49):暫停中的計劃

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49):開發中止的產品

端粒酶反轉錄酵素 (端粒酶或HEST2或端粒酶催化劑亞單位或端粒酶相關蛋白2或EC 2.7.7.49):主要消息與新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1046TDB

Summary:

According to the recently published report 'Telomerase Reverse Transcriptase - Telomerase Reverse Transcriptase'; Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) pipeline Target constitutes close to 31 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes.

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Telomerase reverse transcriptase is a catalytic subunit of the enzyme telomerase. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. It modulates Wnt signaling. It plays important role in aging and anti-apoptosis.

The report 'Telomerase Reverse Transcriptase - Telomerase Reverse Transcriptase' outlays comprehensive information on the Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 8, 2, 1, 8 and 4 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Hematological Disorders, Immunology, Male Health and Metabolic Disorders which include indications Non-Small Cell Lung Cancer, Breast Cancer, Prostate Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Hepatocellular Carcinoma, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Amyotrophic Lateral Sclerosis, Aplastic Anemia, Atherosclerosis, Benign Prostatic Hyperplasia, Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Cervical Cancer, Gastroesophageal (GE) Junction Carcinomas, Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone-Sensitive Prostate Cancer, Leukemias, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Muscle Invasive Bladder Cancer (MIBC), Myelodysplastic Syndrome, Myelofibrosis, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Premature Ageing and Renal Cell Carcinoma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)
  • The report reviews Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Overview
    • Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Companies Involved in Therapeutics Development
    • Argos Therapeutics Inc
    • Asterias Biotherapeutics Inc
    • e-Therapeutics Plc
    • F. Hoffmann-La Roche Ltd
    • Inovio Pharmaceuticals Inc
    • Invectys SA
    • Johnson & Johnson
    • Komipharm International Co Ltd
    • Mediolanum farmaceutici SpA
    • Telocyte LLC
    • TILT Biotherapeutics Ltd
    • Ultimovacs AS
    • Vaxon Biotech
  • Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Drug Profiles
    • AGS-499 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Gene Therapy to Inhibit Telomerase Reverse Transcriptase for Ovarian Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASTVAC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASTVAC-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Dendritic Cell Therapy + TILT-234 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ETS-2300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Telomerase for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Telomerase for Alzheimer's Disease and Atherosclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Telomerase for Aplastic Anemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GX-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imetelstat sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INO-1400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INO-5400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INO-5401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INVAC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KML-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rocapuldencel-T - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Telomerase for Lung Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Telomerase for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • telin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tertomotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UCPVax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UV-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target Telomerase for Cervical Cancer and Solid Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target Telomerase Reverse Transcriptase for Solid Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vbx-011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vbx-016 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vbx-021 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vbx-026 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vx-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vx-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Dormant Products
  • Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Discontinued Products
  • Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 26, 2017: Asterias Receives Regulatory Clearance to Initiate Clinical Study of AST-VAC2 in Subjects with Early and Late Stage Non-Small Cell Lung Cancer
      • Sep 19, 2017: Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at the ESMO 2017 Congress
      • Sep 12, 2017: Argos Therapeutics Reports on Interim Analysis of Phase 3 ADAPT Trial Presented at ESMO 2017 Congress
      • Sep 11, 2017: Rocapuldencel-T Shows Potential Benefit in Metastatic Renal Cell Carcinoma
      • Aug 21, 2017: Argos Therapeutics Announces Interim Analysis of Phase 3 ADAPT Trial to be Presented at ESMO 2017 Congress
      • Aug 14, 2017: Asterias Announces Major AST-VAC2 Development Milestone: First cGMP-Compliant Lot Successfully Manufactured to Support First Clinical Study of AST-VAC2
      • Jul 31, 2017: Geron Announces Updates to Imetelstat Clinical Development
      • Jun 01, 2017: Vaxon announces results of its Phase IIb lung cancer trial of Vx-001, a therapeutic vaccine based on optimized cryptic peptides
      • May 10, 2017: Argos Provides Update on its ADAPT Trial Following Meeting with FDA
      • Apr 26, 2017: Asterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia in 'Cancer'
      • Apr 18, 2017: Argos Reports Interim Results of the ADAPT Trial and Provides Perspective on Decision to Continue the Trial
      • Apr 10, 2017: Geron Announces Completion of Second Internal Data Reviews for Imetelstat Trials Being Conducted by Janssen
      • Apr 05, 2017: Geron Reports Imetelstat Presentation at American Association for Cancer Research Annual Meeting
      • Feb 22, 2017: Independent Data Monitoring Committee Recommends Discontinuation of the ADAPT Phase 3 Clinical Trial of Rocapuldencel-T in Metastatic Renal Cell Carcinoma for Futility Following Its Planned Interim Data Review
      • Jan 19, 2017: Argos Therapeutics Completes Lease Agreement for Commercial Manufacturing Space on the Centennial Campus of North Carolina State University
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Argos Therapeutics Inc, H2 2017
  • Pipeline by Asterias Biotherapeutics Inc, H2 2017
  • Pipeline by e-Therapeutics Plc, H2 2017
  • Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Pipeline by Inovio Pharmaceuticals Inc, H2 2017
  • Pipeline by Invectys SA, H2 2017
  • Pipeline by Johnson & Johnson, H2 2017
  • Pipeline by Komipharm International Co Ltd, H2 2017
  • Pipeline by Mediolanum farmaceutici SpA, H2 2017
  • Pipeline by Telocyte LLC, H2 2017
  • Pipeline by TILT Biotherapeutics Ltd, H2 2017
  • Pipeline by Ultimovacs AS, H2 2017
  • Pipeline by Vaxon Biotech, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Dormant Products, H2 2017 (Contd..2), H2 2017
  • Discontinued Products, H2 2017
  • Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Types, H2 2017
Back to Top